By Toni Vranjes
Irvine's Endocare Inc. has agreed to acquire the prostate-treatment business of a Dallas-based urology services company for $11.2 million in cash and debt.
Endocare develops technology to treat prostate cancer and other diseases. The target company, U.S. Medical Development Inc., distributes ...
Irvine's Endocare Inc. has agreed to acquire the prostate-treatment business of a Dallas-based urology services company for $11.2 million in cash and debt.
Endocare develops technology to treat prostate cancer and other diseases. The target company, U.S. Medical Development Inc., distributes ...
To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In